Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
<p>HRR gene mutations found in WGS/WES or clinical BRCA1/2 mutational testing.</p>
Guardado en:
| Autor principal: | Sanna Pikkusaari (15055802) (author) |
|---|---|
| Otros Autores: | Manuela Tumiati (15011915) (author), Anni Virtanen (15055805) (author), Jaana Oikkonen (14948281) (author), Yilin Li (15055808) (author), Fernando Perez-Villatoro (15055811) (author), Taru Muranen (15055814) (author), Matilda Salko (15055817) (author), Kaisa Huhtinen (15055820) (author), Anna Kanerva (15055823) (author), Heidi Koskela (15055826) (author), Johanna Tapper (15055829) (author), Riitta Koivisto-Korander (15055832) (author), Titta Joutsiniemi (15055835) (author), Ulla-Maija Haltia (15055838) (author), Heini Lassus (15055841) (author), Sampsa Hautaniemi (14948308) (author), Anniina Färkkilä (14948278) (author), Johanna Hynninen (14932815) (author), Sakari Hietanen (14932818) (author), Olli Carpén (14932812) (author), Liisa Kauppi (15055844) (author) |
| Publicado: |
2025
|
| Materias: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Sanna Pikkusaari (15055802)
Publicado: (2025) -
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
por: Stephanie L. Wethington (16354020)
Publicado: (2025) -
Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Arun Kanakkanthara (14937731)
Publicado: (2025) -
Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Arun Kanakkanthara (14937731)
Publicado: (2025) -
Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
por: Chong Kin Liam (15331321)
Publicado: (2025)